相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Histone Deacetylase Inhibitors Equipped with Estrogen Receptor Modulation Activity
Berkley E. Gryder et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Discovery of the First Histone Deacetylase 6/8 Dual Inhibitors
David E. Olson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Quinazolin-4-one Derivatives as Selective Histone Deacetylase-6 Inhibitors for the Treatment of Alzheimer's Disease
Chao-Wu Yu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion
Jing Wang et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Identification of Highly Selective and Potent Histone Deacetylase 3 Inhibitors Using Click Chemistry-Based Combinatorial Fragment Assembly
Takayoshi Suzuki et al.
PLOS ONE (2013)
Estrogen and estrogen receptors in cardiovascular oxidative stress
Paula-Anahi Arias-Loza et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2013)
Tropolones As Lead-Like Natural Products: The Development of Potent and Selective Histone Deacetylase Inhibitors
Sophia N. Ononye et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
Rapid Discovery of Highly Potent and Selective Inhibitors of Histone Deacetylase 8 Using Click Chemistry to Generate Candidate Libraries
Takayoshi Suzuki et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Selective Histone Deacetylase 6 Inhibitors Bearing Substituted Urea Linkers Inhibit Melanoma Cell Growth
Joel A. Bergman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Dual Targeting of Histone Deacetylase and Topoisomerase II with Novel Bifunctional Inhibitors
William Guerrant et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Conjugate of Pt(IV)-Histone Deacetylase Inhibitor as a Prodrug for Cancer Chemotherapy
Jun Yang et al.
MOLECULAR PHARMACEUTICS (2012)
Receptor Tyrosine Kinases and Targeted Cancer Therapeutics
Kenji Takeuchi et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2011)
Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection
Thierry Roger et al.
BLOOD (2011)
Novel trans-platinum complexes of the histone deacetylase inhibitor valproic acid; synthesis, in vitro cytotoxicity and mutagenicity
Darren M. Griffith et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2011)
The Histone Deacetylase Inhibitor Vorinostat Selectively Sensitizes Fibrosarcoma Cells to Chemotherapy
Erik R. Sampson et al.
JOURNAL OF ORTHOPAEDIC RESEARCH (2011)
The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo
Eric Sanchez et al.
LEUKEMIA RESEARCH (2011)
HIV-1 Tat upregulates expression of histone deacetylase-2 (HDAC2) in human neurons: Implication for HIV-associated neurocognitive disorder (HAND)
Zainulabedin M. Saiyed et al.
NEUROCHEMISTRY INTERNATIONAL (2011)
Histone deacetylase inhibitors and HIV latency
David M. Margolis
CURRENT OPINION IN HIV AND AIDS (2011)
Structure-activity relationships for inhibition of inosine monophosphate dehydrogenase and differentiation induction of K562 cells among the mycophenolic acid derivatives
Shinya Mitsuhashi et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2010)
Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylase based on a cinnamic hydroxamic acid core structure
Liqiang Chen et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2010)
CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity
Cheng-Jung Lai et al.
CANCER RESEARCH (2010)
DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
Yves Pommier et al.
CHEMISTRY & BIOLOGY (2010)
Targeted Cancer Therapies in the Twenty-First Century: Lessons From Imatinib
F. Stegmeier et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer
Xiong Cai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Novel Chimeric Histone Deacetylase Inhibitors: A Series of Lapatinib Hybrides as Potent Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and Histone Deacetylase Activity
Siavosh Mahboobi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor
David Moffat et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A
Kyle V. Butler et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2010)
A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity
Darren Griffith et al.
CHEMICAL COMMUNICATIONS (2009)
IMP Dehydrogenase: Structure, Mechanism, and Inhibition
Lizbeth Hedstrom
CHEMICAL REVIEWS (2009)
Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma
Gonzalo Lopez et al.
CLINICAL CANCER RESEARCH (2009)
Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise
Antonello Mai et al.
CURRENT PHARMACEUTICAL DESIGN (2009)
Sorafenib A Review of its Use in Advanced Hepatocellular Carcinoma
Gillian M. Keating et al.
DRUGS (2009)
Identification of IMPDH2 as a tumor-associated antigen in colorectal cancer using immunoproteomics analysis
Yujun He et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2009)
An Insight to the Dynamics of Conserved Water Molecular Triad in IMPDH II (Human): Recognition of Cofactor and Substrate to Catalytic Arg 322
Hridoy R. Bairagya et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2009)
Design of Chimeric Histone Deacetylase- and Tyrosine Kinase-Inhibitors: A Series of Imatinib Hybrides as Potent Inhibitors of Wild-Type and Mutant BCR-ABL, PDGF-Rβ, and Histone Deacetylases
Siavosh Mahboobi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Hydroxamic Acid Derivatives of Mycophenolic Acid Inhibit Histone Deacetylase at the Cellular Level
Daniela I. Batovska et al.
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY (2008)
Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure
Pasquale Gallo et al.
CARDIOVASCULAR RESEARCH (2008)
Structural origin of selectivity in class II-selective histone deacetylase inhibitors
Guillermina Estiu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas
S. Balasubramanian et al.
LEUKEMIA (2008)
Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment
Liqiang Chen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor
Alexander Yurek-George et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group
Thomas Beckers et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: A Gynecologic Oncology Group Study
Meenakshi Singh et al.
GYNECOLOGIC ONCOLOGY (2007)
Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors
Keris KrennHrubec et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
2-aminothiazole as a novel kinase inhibitor template.: Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor
Jagabandhu Das et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Molecular aspects of antitumor effects of a new platinum(IV) drug
Jana Kasparkova et al.
MOLECULAR PHARMACOLOGY (2006)
Estrogen receptors: Role in breast cancer
M. J. Duffy
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2006)
Dissecting the biological functions of Drosophila histone deacetylases by RNA interference and transcriptional profiling
Cristiana Foglietti et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation
Kevin Pruitt et al.
PLOS GENETICS (2006)
Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589
DZ Qian et al.
CLINICAL CANCER RESEARCH (2006)
Mycophenolic acid-induced replication arrest, differentiation markers and cell death of androgen-independent prostate cancer cells DU145
D Floryk et al.
CANCER LETTERS (2006)
Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: Histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520
A Bieler et al.
HUMAN GENE THERAPY (2006)
Histone deacetylase 6 regulates human immunodeficiency virus type 1 infection
A Valenzuela-Fernández et al.
MOLECULAR BIOLOGY OF THE CELL (2005)
Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance
Y Hirokawa et al.
CANCER BIOLOGY & THERAPY (2005)
HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor
JJ Kovacs et al.
MOLECULAR CELL (2005)
Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation
R Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Histone metabolic pathways and chromatin assembly factors as proliferation markers
SE Polo et al.
CANCER LETTERS (2005)
Stat3 dimerization regulated by reversible acetylation of a single lysine residue
ZL Yuan et al.
SCIENCE (2005)
Timeline - Chemotherapy and the war on cancer
BA Chabner et al.
NATURE REVIEWS CANCER (2005)
Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation
L Gaughan et al.
NUCLEIC ACIDS RESEARCH (2005)
Shaping the nuclear action of NF-κB
LF Chen et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Estrogen receptors α and β in choroid plexus epithelial cells in Alzheimer's disease
BC Hong-Goka et al.
NEUROSCIENCE LETTERS (2004)
Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis
HY Cohen et al.
MOLECULAR CELL (2004)
Functional regulation of GATA-2 by acetylation
F Hayakawa et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2004)
Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo
JY Luo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584
DZ Qian et al.
CANCER RESEARCH (2004)
Regulation of human SRY subcellular distribution by its acetylation/deacetylation
L Thevenet et al.
EMBO JOURNAL (2004)
Differentiation of human prostate cancer PC-3 cells induced by inhibitors of inosine 5′-monophosphate dehydrogenase
D Floryk et al.
CANCER RESEARCH (2004)
Transforming growth factor-β stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation
YH Jin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60
JH Patel et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression
L Ylisastigui et al.
AIDS (2004)
Post-translational modification of p53 in tumorigenesis
AM Bode et al.
NATURE REVIEWS CANCER (2004)
Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamine acid
DC Marchion et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2004)
Sirtuins: Sir2-related NAD-dependent protein deacetylases
BJ North et al.
GENOME BIOLOGY (2004)
Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor α
H Kawai et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Structural biasing elements for in-cell histone deacetylase paralog selectivity
JC Wong et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2003)
Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays
SJ Haggarty et al.
CHEMISTRY & BIOLOGY (2003)
Coactivator-dependent acetylation stabilizes members of the SREBP family of transcription factors
V Giandomenico et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Histone deacetylases (HDACs): characterization of the classical HDAC family
AJM De Ruijter et al.
BIOCHEMICAL JOURNAL (2003)
Post-activation turn-off of NF-κB-dependent transcription is regulated by acetylation of p65
R Kiernan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Identification of novel isoform-selective inhibitors within class I histone deacetylases
ED Hu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Regulation and destabilization of HIF-1α by ARD1-mediated acetylation
JW Jeong et al.
CELL (2002)
MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation
A Ito et al.
EMBO JOURNAL (2002)
Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis
L Rössig et al.
CIRCULATION RESEARCH (2002)
Control of Smad7 stability by competition between acetylation and ubiquitination
E Grönroos et al.
MOLECULAR CELL (2002)
Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor.
L Gaughan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Molecular aspects of resistance to antitumor platinum drugs
V Brabec et al.
DRUG RESISTANCE UPDATES (2002)
Particular aspects of platinum compounds used at present in cancer treatment
B Desoize et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2002)
Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function
MF Fu et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Modulation of HMG-N2 binding to chromatin by butyrate-induced acetylation in human colon adenocarcinoma cells
H Lührs et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis
HJ Kwon et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling
CF Deroanne et al.
ONCOGENE (2002)
Histone deacetylases and cancer: Causes and therapies
PA Marks et al.
NATURE REVIEWS CANCER (2001)
Regulation of transcription factor YY1 by acetylation and deacetylation
YL Yao et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Duration of nuclear NF-κB action regulated by reversible acetylation
LF Chen et al.
SCIENCE (2001)
Coordination of a transcriptional switch by HMGI(Y) acetylation
N Munshi et al.
SCIENCE (2001)
Direct acetylation of the estrogen receptor α hinge region by p300 regulates transactivation and hormone sensitivity
CG Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Site-specific acetylation by p300 or CREB binding protein regulates erythroid Kruppel-like factor transcriptional activity via its interaction with the SWI-SNF complex
WJ Zhang et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
MS Kim et al.
NATURE MEDICINE (2001)
Genomewide studies of histone deacetylase function in yeast
BE Bernstein et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
The protein tyrosine kinase family of the human genome
DR Robinson et al.
ONCOGENE (2000)
Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells
PA Marks et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation
MF Fu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Acetylation of importin-α nuclear import factors by CBP/p300
AJ Bannister et al.
CURRENT BIOLOGY (2000)
E2F family members are differentially regulated by reversible acetylation
G Marzio et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Regulation of E2F1 activity by acetylation
MA Martínez-Balbás et al.
EMBO JOURNAL (2000)
Acetylation of GATA-3 affects T-cell survival and homing to secondary lymphoid organs
T Yamagata et al.
EMBO JOURNAL (2000)
分享论文
